BIFIDOBACTERIUM LACTIS Bi-07™

The B. infantis strain used in the studies by Wagner et al. was B. lactis Bi-07™ (described in the articles as “a human isolate obtained from Rhone-Poulenc, Madison, Wisconsin”). B. lactis Bi-07™ has been deposited in the American Type Culture Collection’s safe deposit as SD5220.

In vitro trials

Immune system modulation


Antibiotic resistance


Antipathogenic activity and/or Bacteriocins


Prebiotic utilization


Adherence


3. Candela M, Biagi E, Centanni M, Turroni S, Vici M, Musiani F, Vitali B, Bergmann S,


Proteomics


Oxalate degradation


Animal trials

Safety


Immune system modulation


Antipathogenic activity


Anti-pain/analgesic


Obesity


Human clinical studies

Safety and colonization


Gastrointestinal ecology


Synbiotic


Immune system enhancement


Allergy treatment


General health


Gastrointestinal functionality - Diarrhea and irritable bowel syndrome


Bi-07™ improve symptoms of bloating patients with functional bowel disorders (FBD). International Probiotic Conference (IPC), Slovakia.


10. [Case studies] Lukaczer D. Evaluating the Effects of Specialized Nutritional Support, Including strain-certified Lactobacillus acidophilus NCFM® and Bifidobacterium lactis Bi-07™, in a Patient with Irritable Bowel Syndrome. (Case study #1150). San Clemente (CA): Metagenics, Inc. See file “metagenics search NCFM®” – Several case studies exist, but not available in full text.

**Product functionality**


